Puretech Health

PureTech's deupirfenidone demonstrated potential to stabilize lung function decline over 26 weeks in idiopathic pulmonary fibrosis patients, an unprecedented achievement in IPF treatment.

• Seaport Therapeutics has raised $225 million in Series B funding, led by General Atlantic, to develop innovative oral treatments for depression and anxiety using their proprietary Glyph technology. • The company's lead candidate SPT-300, an oral prodrug of allopregnanolone for major depressive disorder, has advanced to Phase 2b trials with potential for regulatory submission. • Seaport's pipeline includes SPT-320 for generalized anxiety disorder and SPT-348, representing the first potential new anxiety treatment mechanism in decades.

• VE303, a defined bacterial consortium, significantly reduced the risk of recurrent Clostridioides difficile infection (rCDI) in a Phase 2 trial compared to placebo. • The investigational therapy's precisely defined composition enables detailed studies of its mechanisms, revealing how it restores gut health and reduces inflammation. • Multi-omic analyses identified predictors of VE303 colonization and clinical response, including antibiotic history and levels of key metabolites. • A Phase 3 trial is underway, with topline data expected in 2026, to confirm VE303's efficacy and safety in preventing rCDI.

The FDA has granted Fast Track designation to LYT-200, PureTech's anti-galectin-9 monoclonal antibody, for treating acute myeloid leukemia (AML).

Seaport Therapeutics' SPT-300, an allopregnanolone prodrug, demonstrates good tolerability in a Phase I trial with 99 healthy volunteers, highlighting its safety profile.

The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment.